Middle East Pharmaceutical Industries Co. (4016.SR)
SAR 119.8
(-0.33%)
SAR 119.8
(-0.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 85.13 Million SAR | 5.16% |
| 2022 | 81.12 Million SAR | -5.96% |
| 2021 | 82.97 Million SAR | -4.26% |
| 2020 | 89.35 Million SAR | 30.25% |
| 2019 | 68.76 Million SAR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 24.52 Million SAR | 59.38% |
| 2024 Q1 | 21.7 Million SAR | -47.11% |
| 2023 Q4 | 29.08 Million SAR | 0.0% |
| 2023 Q3 | 29.08 Million SAR | 22.0% |
| 2023 FY | - SAR | 11.92% |
| 2023 Q2 | 23.84 Million SAR | 484.08% |
| 2023 Q1 | 4.08 Million SAR | -83.22% |
| 2022 Q1 | 13.8 Million SAR | 0.0% |
| 2022 FY | - SAR | -5.96% |
| 2022 Q4 | 24.32 Million SAR | 0.0% |
| 2022 Q2 | 26.06 Million SAR | 88.83% |
| 2022 Q3 | 24.32 Million SAR | -6.66% |
| 2021 FY | - SAR | -4.26% |
| 2020 FY | - SAR | 30.25% |
| 2019 FY | - SAR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Al-Dawaa Medical Services Company | 830.43 Million SAR | 89.748% |
| Nahdi Medical Company | 1.64 Billion SAR | 94.82% |
| Al-Razi Medical Co. | 5.64 Million SAR | -1406.862% |
| Almujtama Alraida Medical Co. | 19.53 Million SAR | -335.864% |